{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:56:44Z","timestamp":1763359004996,"version":"3.38.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","fsigenetics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International: Genetics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.fsigen.2024.103219","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T03:14:24Z","timestamp":1735096464000},"page":"103219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report"],"prefix":"10.1016","volume":"76","author":[{"given":"G.","family":"Drevin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Baudriller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Renard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Malbranque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Briet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Abbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fsigen.2024.103219_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.863088","article-title":"Entactogens: how the name for a novel class of psychoactive agents originated","volume":"13","author":"Nichols","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.fsigen.2024.103219_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fpsyt.2019.00138","article-title":"A Review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy","volume":"10","author":"Sessa","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.fsigen.2024.103219_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1096298","article-title":"Perspectives on the therapeutic potential of MDMA: a nation-wide exploratory survey among substance users","volume":"14","author":"Jones","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.fsigen.2024.103219_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/02791072.2014.873690","article-title":"The potential dangers of using MDMA for psychotherapy","volume":"46","author":"Parrott","year":"2014","journal-title":"J. Psychoact. Drugs"},{"unstructured":"European Monitoring Centre for Drug and Drug Addiction (EMCDDA), European drug report 2023: trends and developments, 2023.","key":"10.1016\/j.fsigen.2024.103219_bib5"},{"issue":"11","key":"10.1016\/j.fsigen.2024.103219_bib6","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/add.15493","article-title":"Trends in MDMA-related mortality across four countries","volume":"116","author":"Roxburgh","year":"2021","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12024-010-9220-7","article-title":"\u201cEcstasy\u201d associated deaths: what is a fatal concentration\u00a0? Analysis of a case series","volume":"7","author":"Milroy","year":"2011","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.fsigen.2024.103219_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.102630","article-title":"MDMA-related deaths in Australia 2000 to 2018","volume":"76","author":"Roxburgh","year":"2020","journal-title":"Int. J. Drug Policy"},{"issue":"5","key":"10.1016\/j.fsigen.2024.103219_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jat\/29.5.296","article-title":"MDMA and MDA concentrations in antemortem and postmortem specimens in fatalities following hospital admission","volume":"29","author":"Elliott","year":"2005","journal-title":"J. Anal. Toxicol."},{"issue":"11","key":"10.1016\/j.fsigen.2024.103219_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/toxics9110292","article-title":"Pharmacogenetics and forensic toxicology: a new step towards a multidisciplinary approach","volume":"9","author":"Di Nunno","year":"2021","journal-title":"Toxics"},{"issue":"1-3","key":"10.1016\/j.fsigen.2024.103219_bib11","first-page":"44","article-title":"Pharmacogenetics in medico-legal context","volume":"203","author":"Sajantila","year":"2010"},{"issue":"1","key":"10.1016\/j.fsigen.2024.103219_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11419-019-00512-y","article-title":"A fatal case report of acute yohimbine intoxication","volume":"38","author":"Drevin","year":"2020","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.fsigen.2024.103219_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110743","article-title":"Chemsex\/slamsex-related intoxications: a case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature","volume":"321","author":"Drevin","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2024.103219_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2024.112030","article-title":"Synthetic cathinones in drug-facilitated sexual assault: a case report involving the novel generation substituted cathinone N-ethylpentedrone and a review of the literature","volume":"359","author":"Drevin","year":"2024","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/FTD.0b013e3181684fa0","article-title":"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults","volume":"30","author":"Kolbrich","year":"2008","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.fsigen.2024.103219_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1749-6632.2000.tb05199.x","article-title":"Pharmacology of MDMA in humans","volume":"914","author":"De La Torre","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"47","key":"10.1016\/j.fsigen.2024.103219_bib17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0006-2952(94)90386-7","article-title":"The demethylenation of methylenedioxymethamphetamine (\u201cecstasy\u201d) by debrisoquine hydroxylase (CYP2D6)","volume":"7","author":"Tucker","year":"1994","journal-title":"Biochem Pharm."},{"issue":"357","key":"10.1016\/j.fsigen.2024.103219_bib18","first-page":"163","article-title":"Is there an impact of CYP2D6 genotype on the toxicity of ecstasy and related designer drugs?","volume":"4","author":"Schwab","year":"1998","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13556219872119","article-title":"MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6","volume":"3","author":"O\u2019Donohoe","year":"1998","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.fsigen.2024.103219_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2125.2002.01574.x","article-title":"CYP2D6 deficiency, a factor in ecstasy related death?","volume":"54","author":"Gilhooly","year":"2002","journal-title":"Br. J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.fsigen.2024.103219_bib21","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.108.026393","article-title":"Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion","volume":"37","author":"Perfetti","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.fsigen.2024.103219_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027206","article-title":"The Influence of genetic and environmental factors among MDMA users in cognitive performance","volume":"6","author":"Cuy\u00e0s","year":"2011","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.fsigen.2024.103219_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047599","article-title":"Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)","volume":"7","author":"Pardo-Lozano","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0269881111434624","article-title":"Ecstasy (MDMA)-induced hyponatremia is associated with genetic variants in CYP2D6 and COMT","volume":"26","author":"Aitchison","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","article-title":"Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects","volume":"27","author":"Vizeli","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.fsigen.2024.103219_bib26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/10408444.2012.725029","article-title":"Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug\u2013drug interactions","volume":"42","author":"Rietjens","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"issue":"5","key":"10.1016\/j.fsigen.2024.103219_bib27","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/jnc.15348","article-title":"Methylenedioxymethamphetamine (MDMA): serotonergic and dopaminergic mechanisms related to its use and misuse","volume":"157","author":"Schenk","year":"2021","journal-title":"J. Neurochem"},{"issue":"3","key":"10.1016\/j.fsigen.2024.103219_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.162.3.609","article-title":"Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users","volume":"162","author":"Roiser","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.fsigen.2024.103219_bib29","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/0269881109354926","article-title":"The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users","volume":"24","author":"Fagundo","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.fsigen.2024.103219_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1369-1600.2009.00180.x","article-title":"5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study","volume":"15","author":"Martin-Santos","year":"2010","journal-title":"Addict. Biol."}],"container-title":["Forensic Science International: Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1872497324002151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1872497324002151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:43:34Z","timestamp":1740743014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1872497324002151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"alternative-id":["S1872497324002151"],"URL":"https:\/\/doi.org\/10.1016\/j.fsigen.2024.103219","relation":{},"ISSN":["1872-4973"],"issn-type":[{"type":"print","value":"1872-4973"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interest and limits of using pharmacogenetics in MDMA-related fatalities: A case report","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International: Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fsigen.2024.103219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103219"}}